Inhibition of extracellular signal-regulated kinase (ERK) signaling participates in repression of nuclear factor (NF)-κB activity by glucocorticoids

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1793, Issue 3, 2009, Pages 439-446

  Bladh, Lars Göran ^a   Johansson Haque, Krishan ^a   Rafter, Ingalill ^a   Nilsson, Stefan ^b   Okret, Sam ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Karo Bio   (Sweden)

Author keywords

Cross talk; ERK; Glucocorticoid; MAPK signaling; MKP 1 DUSP1; NF B

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

DEXAMETHASONE; DUAL SPECIFICITY PHOSPHATASE 1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLUCOCORTICOIDS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; TRANSFECTION;

EID: 60849086171     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2008.11.013     Document Type: Article

References (47)

1. Bladh L.G., Lidén J., Pazirandeh A., Rafter I., Dahlman-Wright K., Nilsson S., and Okret S. Identification of target genes involved in the antiproliferative effect of glucocorticoids reveals a role for nuclear factor-(kappa)B repression. Mol. Endocrinol. 19 (2005) 632-643
2. De Bosscher K., Vanden Berghe W., and Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24 (2003) 488-522
3. Reichardt H.M., Tuckermann J.P., Göttlicher M., Vujic M., Weih F., Angel P., Herrlich P., and Schütz G. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 20 (2001) 7168-7173
4. Necela B.M., and Cidlowski J.A. Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc. Am. Thorac. Soc. 1 (2004) 239-246
5. Karin M., Yamamoto Y., and Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3 (2004) 17-26
6. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109 (2002) S81-S96
7. Schmitz M.L., Bacher S., and Kracht M. I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations. Trends Biochem. Sci. 26 (2001) 186-190
8. Vermeulen L., De Wilde G., Van Damme P., Vanden Berghe W., and Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 22 (2003) 1313-1324
9. Ito K., Chung K.F., and Adcock I.M. Update on glucocorticoid action and resistance. J. Allergy Clin. Immunol. 117 (2006) 522-543
10. Liden J., Rafter I., Truss M., Gustafsson J.A., and Okret S. Glucocorticoid effects on NF-kappaB binding in the transcription of the ICAM-1 gene. Biochem. Biophys. Res. Commun. 273 (2000) 1008-1014
11. Nissen R.M., and Yamamoto K.R. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 14 (2000) 2314-2329
12. Luecke H.F., and Yamamoto K.R. The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression. Genes Dev. 19 (2005) 1116-1127
13. Reily M.M., Pantoja C., Hu X., Chinenov Y., and Rogatsky I. The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. EMBO J. 25 (2006) 108-117
14. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., and Glass C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122 (2005) 707-721
15. Glass C.K., and Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat. Rev., Immunol. 6 (2006) 44-55
16. Cissel D.S., and Beaven M.A. Disruption of Raf-1/heat shock protein 90 complex and Raf signaling by dexamethasone in mast cells. J. Biol. Chem. 275 (2000) 7066-7070
17. Clark A.R., and Lasa M. Crosstalk between glucocorticoids and mitogen-activated protein kinase signalling pathways. Curr. Opin. Pharmacol. 3 (2003) 404-411
18. Engelbrecht Y., de Wet H., Horsch K., Langeveldt C.R., Hough F.S., and Hulley P.A. Glucocorticoids induce rapid up-regulation of mitogen-activated protein kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human and mouse osteoblast cell lines. Endocrinology 144 (2003) 412-422
19. Kassel O., Sancono A., Kratzschmar J., Kreft B., Stassen M., and Cato A.C. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J. 20 (2001) 7108-7116
20. Rider L.G., Hirasawa N., Santini F., and Beaven M.A. Activation of the mitogen-activated protein kinase cascade is suppressed by low concentrations of dexamethasone in mast cells. J. Immunol. 157 (1996) 2374-2380
21. Gonzalez M.V., Gonzalez-Sancho J.M., Caelles C., Munoz A., and Jimenez B. Hormone-activated nuclear receptors inhibit the stimulation of the JNK and ERK signalling pathways in endothelial cells. FEBS Lett. 459 (1999) 272-276
22. Firestein G.S., and Manning A.M. Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum. 42 (1999) 609-621
23. Farooq A., and Zhou M.M. Structure and regulation of MAPK phosphatases. Cell. Signal. 16 (2004) 769-779
24. Salojin K.V., Owusu I.B., Millerchip K.A., Potter M., Platt K.A., and Oravecz T. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J. Immunol. 176 (2006) 1899-1907
25. Wu J.J., Roth R.J., Anderson E.J., Hong E.G., Lee M.K., Choi C.S., Neufer P.D., Shulman G.I., Kim J.K., and Bennett A.M. Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metab. 4 (2006) 61-73
26. Wu W., Pew T., Zou M., Pang D., and Conzen S.D. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J. Biol. Chem. 280 (2005) 4117-4124
27. Chen P., Li J., Barnes J., Kokkonen G.C., Lee J.C., and Liu Y. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J. Immunol. 169 (2002) 6408-6416
28. Lasa M., Abraham S.M., Boucheron C., Saklatvala J., and Clark A.R. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol. Cell. Biol. 22 (2002) 7802-7811
29. Roger T., Chanson A.L., Knaup-Reymond M., and Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur. J. Immunol. 35 (2005) 3405-3413
30. Toh M.L., Yang Y., Leech M., Santos L., and Morand E.F. Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoids. Arthritis Rheum. 50 (2004) 3118-3128
31. Usmani O.S., Ito K., Maneechotesuwan K., Ito M., Johnson M., Barnes P.J., and Adcock I.M. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am. J. Respir. Crit. Care Med. 172 (2005) 704-712
32. Wu W., Chaudhuri S., Brickley D.R., Pang D., Karrison T., and Conzen S.D. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res. 64 (2004) 1757-1764
33. Johansson-Haque K., Palanichamy E., and Okret S. Stimulation of MAPK-phosphatase 1 gene expression by glucocorticoids occurs through a tethering mechanism involving C/EBP. J. Mol. Endocrinol. 41 (2008) 239-249
34. Abraham S.M., Lawrence T., Kleiman A., Warden P., Medghalchi M., Tuckermann J., Saklatvala J., and Clark A.R. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J. Exp. Med. 203 (2006) 1883-1889
35. Maier J.V., Brema S., Tuckermann J., Herzer U., Klein M., Stassen M., Moorthy A., and Cato A.C. Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol. Endocrinol. 21 (2007) 2663-2671
36. Bladh L.G., Lidén J., Dahlman-Wright K., Reimers M., Nilsson S., and Okret S. Identification of endogenous glucocorticoid repressed genes differentially regulated by a glucocorticoid receptor mutant able to separate between nuclear factor-kappaB and activator protein-1 repression. Mol. Pharmacol. 67 (2005) 815-826
37. van de Stolpe A., Caldenhoven E., Stade B.G., Koenderman L., Raaijmakers J.A., Johnson J.P., and van der Saag P.T. 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J. Biol. Chem. 269 (1994) 6185-6192
38. Pages G., Brunet A., L'Allemain G., and Pouyssegur J. Constitutive mutant and putative regulatory serine phosphorylation site of mammalian MAP kinase kinase (MEK1). EMBO J. 13 (1994) 3003-3010
39. Lidén J., Delaunay F., Rafter I., Gustafsson J.-Å., and Okret S. A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation. J. Biol. Chem. 272 (1997) 21467-21472
40. Li L.B., Goleva E., Hall C.F., Ou L.S., and Leung D.Y. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. J. Allergy Clin. Immunol. 114 (2004) 1059-1069
41. Rogatsky I., Logan S.K., and Garabedian M.J. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2050-2055
42. Tsitoura D.C., and Rothman P.B. Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells. J. Clin. Invest. 113 (2004) 619-627
43. Clark A.R. MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids?. J. Endocrinol. 178 (2003) 5-12
44. Abraham S.M., and Clark A.R. Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem. Soc. Trans. 34 (2006) 1018-1023
45. Horsch K., de Wet H., Schuurmans M.M., Allie-Reid F., Cato A.C., Cunningham J., Burrin J.M., Hough F.S., and Hulley P.A. Mitogen-activated protein kinase phosphatase 1/dual specificity phosphatase 1 mediates glucocorticoid inhibition of osteoblast proliferation. Mol. Endocrinol. 21 (2007) 2929-2940
46. Wu J.J., and Bennett A.M. Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling. J. Biol. Chem. 280 (2005) 16461-16466
47. Teng C.H., Huang W.N., and Meng T.C. Several dual specificity phosphatases coordinate to control the magnitude and duration of JNK activation in signaling response to oxidative stress. J. Biol. Chem. 282 (2007) 28395-28407